 Pancreatic cancer patients can be divided into two groups or subtypes and then one subtype of pancreatic cancer is especially deadly with the patients coming to the disease within months of diagnosis. The work in our lab has been focused on trying to understand the biology and the reasons behind why these patients with this most aggressive form of pancreatic cancer do so much worse and so this work led to the identification of a gene or a transcription factor called TP63 that is specifically expressed in this particularly aggressive form of pancreatic cancer. So interestingly TP63 is a gene that's not normally expressed at all in a normal pancreas, it's actually typically expressed in the skin and some other tissues. So to find TP63 expressed in the pancreas was very unusual and even more unusual is that these cancer cells become addicted to this p63 expression so much so that we believe that if you can inhibit p63 activity or stop p63 from becoming activated in the first place this may be a beneficial treatment strategy for this group of patients.